A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Pharmacodynamics of Increasing Subcutaneous Doses of SELA-070 in Healthy Adult Smokers
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2018
At a glance
- Drugs SELA-070 (Primary)
- Indications Smoking withdrawal
- Focus Adverse reactions
- Sponsors Selecta Biosciences
- 15 Nov 2018 Status changed from active, no longer recruiting to completed.
- 17 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 24 Jul 2018 Planned End Date changed from 1 Sep 2018 to 31 Dec 2018.